Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974580 · ClinicalTrials.gov registry record · Phase 4
Research and Innovation to Stop E-cigarette/Vaping in Young Adults
A Phase 4 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 508
- Enrollment target
NCT04974580: Completed Phase 4 study, sponsored by Ohio State University.
NCT04974580 is a Phase 4 study that has completed, run by Ohio State University. The registered enrollment target is 508 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04974580, a Phase 4 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 508 participants
- Enrollment target
Study Summary
The aim of this study is to test intervention components to help young adults quit vaping. A 2x2 factorial design will be used where all participants receive quitline-delivered behavioral phone counseling, and components to be tested are a digital intervention (with text and online cessation support) and nicotine replacement therapy (NRT). The research questions and hypotheses for this study are: 1. Which components and combinations of intervention yield the greatest success rates for exclusive vaping cessation among young adult exclusive e-cigarette users? H1: The complete condition (NRT + digital) will yield significantly higher rates of cessation compared to the control condition (quitline only). 2. Does 8 weeks of nicotine replacement therapy (NRT) improve initial cessation outcomes relative to no NRT. H2: Providing NRT will yield significantly higher quit rates compared to the No NRT condition. 3. Do tailored text-messages and online support during cessation improve initial cessation outcomes relative to no digital content? Are young adult vapers engaged with and satisfied with digital cessation tools? H3: Digital support will yield significantly higher quit rates compared to no digital support. H4: Higher engagement in digital content will be associated with higher cessation success rates.
Primary Outcome
Self-report of no use of e-cigarettes in the past 7 days at the time of the 3-month outcome survey.
Interventions
- DRUG Nicotine patch
- BEHAVIORAL Phone Counseling
- BEHAVIORAL Digital Coaching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 4 |
What the finished NCT04974580 record still lists
NCT04974580 is an interventional study that assigns participants to a tested intervention. The registered 508 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Nicotine patch is the first listed.
NCT04974580 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04974580 about?
NCT04974580 is a clinical study titled "Research and Innovation to Stop E-cigarette/Vaping in Young Adults". The aim of this study is to test intervention components to help young adults quit vaping. A 2x2 factorial design will be used where all participants receive quitline-delivered behavioral phone counseling, and components to be tested are a digital intervention (with text and online cessation support...
What is the current status of trial NCT04974580?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 508 participants. The study started on 2021-07-28. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT04974580?
The interventions under investigation include: Nicotine patch (DRUG), Phone Counseling (BEHAVIORAL), Digital Coaching (BEHAVIORAL).
Who is sponsoring clinical trial NCT04974580?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04974580's enrollment target sits among peer trials
508 162nd of 2000 higher than 1,839 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- NCT07484217 · 508 participants · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI